Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Biofrontera AG Sponsored ADR (BFRA : NSDQ)
 
 • Company Description   
Biofrontera AG is a biopharmaceutical company. It engaged in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases. The company's products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions which can sometimes lead to skin cancer as well as the treatment of certain forms of basal cell carcinoma in the European Union. Biofrontera AG is based in Leverkusen, Germany.

Number of Employees: 149

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.40 Daily Weekly Monthly
20 Day Moving Average: 69,327 shares
Shares Outstanding: 28.36 (millions)
Market Capitalization: $96.42 (millions)
Beta: 1.15
52 Week High: $9.29
52 Week Low: $3.32
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -37.04% -35.07%
12 Week -39.59% -40.19%
Year To Date -53.36% -57.67%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
HEMMELRATHER WEG 201
-
LEVERKUSEN,2M D-51377
DEU
ph: 011-49-2148-7600
fax: 49-02-1487-6320
ir@biofrontera.com http://www.biofrontera.com
 
 • General Corporate Information   
Officers
Hermann Lubbert - Chief Executive Officer and Chairman
Jurgen Baumann - Vice Chairman
Ludwig Lutter - Chief Financial Officer
John Borer - Director
Reinhard Eyring - Director

Peer Information
Biofrontera AG Sponsored ADR (CORR.)
Biofrontera AG Sponsored ADR (RSPI)
Biofrontera AG Sponsored ADR (CGXP)
Biofrontera AG Sponsored ADR (BGEN)
Biofrontera AG Sponsored ADR (GTBP)
Biofrontera AG Sponsored ADR (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09075G105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 04/11/22
Share - Related Items
Shares Outstanding: 28.36
Most Recent Split Date: (:1)
Beta: 1.15
Market Capitalization: $96.42 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 04/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 5.14
Price/Cash Flow: -
Price / Sales: 2.92
EPS Growth
vs. Year Ago Period: 14.29%
vs. Previous Quarter: -41.18%
Sales Growth
vs. Year Ago Period: 15.12%
vs. Previous Quarter: -30.87%
ROE
09/30/21 - -93.31
06/30/21 - -119.88
03/31/21 - -133.84
ROA
09/30/21 - -24.02
06/30/21 - -24.78
03/31/21 - -20.72
Current Ratio
09/30/21 - 1.26
06/30/21 - 3.94
03/31/21 - 4.09
Quick Ratio
09/30/21 - 1.13
06/30/21 - 3.58
03/31/21 - 3.65
Operating Margin
09/30/21 - -59.44
06/30/21 - -59.70
03/31/21 - -43.10
Net Margin
09/30/21 - -59.44
06/30/21 - -59.70
03/31/21 - -43.10
Pre-Tax Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Book Value
09/30/21 - 0.66
06/30/21 - 0.92
03/31/21 - 1.09
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - 0.13
06/30/21 - 0.98
03/31/21 - 0.81
Debt-to-Capital
09/30/21 - 11.18
06/30/21 - 49.38
03/31/21 - 44.84
 

Powered by Zacks Investment Research ©